Articles by Patricia Van Arnum - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Patricia Van Arnum

AstraZeneca Issues Statement on Competitor to Nexium

Dec 18, 2013

AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe

Dec 18, 2013

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

Pfizer, Teva Settle Patent Litigation on Viagra

Dec 18, 2013

Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

GlaxoSmithKline To Invest in UK-Based Manufacturing

Dec 12, 2013

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

Teva Releases Financial Guidance Dependent on Copaxone Generic Competition

Dec 12, 2013

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

Roche, Prothena Form mAb Pact

Dec 12, 2013

Roche and Prothena sign deal worth up to $600 million to develop and commercialize antibodies that target alpha-synuclein.

Pharmaceutical Industry Growth Rebounds in Five-Year Outlook

Nov 22, 2013

Annual growth in spending for medicines is expected to rise from 2-3% in 2013 to 5-7% in 2017, the highest pace of growth since 2009.

AstraZeneca, Bristol-Myers Squibb Recall Certain Lots of Bydureon

Sep 24, 2013

AstraZeneca, Bristol-Myers Squibb recall certain lots of of their antidiabetes drug Bydureon (eventide) due to manufacturing records that batches may contain underfilled vials.

Elan Proceeds with Formal Sale Process of Company; Royalty Pharma Drops Bid

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.
Jun 19, 2013

The move follows rejection of Elan shareholders of certain key deals and withdrawal of Royalty Pharma bid.

ADVERTISEMENT

ADVERTISEMENT

Click here